Literature DB >> 19949912

Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma.

Constantinos Giaginis1, Gerasimos Tsourouflis, Adamantia Zizi-Serbetzoglou, Gregorios Kouraklis, Elli Chatzopoulou, Konstantina Dimakopoulou, Stamatios E Theocharis.   

Abstract

Ephrin (Eph) receptors have been reported to be frequently overexpressed in a wide variety of cancer types, being associated with tumor growth, invasion, metastasis and angiogenesis. The aim of the present study was to evaluate the clinical significance of Eph-A1, -A2, -A4, -A5 and -A7 expression in pancreatic ductal adenocarcinoma. Eph-A1, -A2, -A4, -A5 and -A7 expression and staining intensity were assessed immunohistochemically in tumoral samples of 67 pancreatic adenocarcinoma patients and were statistically analyzed in relation to clinicopathological characteristics, tumor proliferative capacity and patients' survival. Eph receptors were abundantly expressed in pancreatic ductal adenocarcinoma cases examined. Eph-A1 staining intensity was significantly associated with tumor size (pT, p = 0.008) and tumor histopathological stage (pStage, p = 0.012). Eph-A2 expression was significantly associated with patients' age (p = 0.007), while Eph-A4 and Eph-A5 with tumor proliferative capacity (p = 0.019 and p = 0.011, respectively). Pancreatic adenocarcinoma patients with moderate/intense Eph-A5 or Eph-A7 staining presented significantly shorter survival times compared to those with negative/mild one (log-rank test, p = 0.024 and p = 0.009, respectively). Multivariate analysis identified Eph-A5 and Eph-A7 staining intensity as independent prognostic factors (p = 0.048 and p = 0.004, respectively). In conclusion, the present study revealed that Eph receptors were associated with pancreatic cancer characteristics, supporting evidence for their potential clinical application in management and prognosis of pancreatic adenocarcinoma patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19949912     DOI: 10.1007/s12253-009-9221-6

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  41 in total

Review 1.  The ephrins and Eph receptors in angiogenesis.

Authors:  Nikki Cheng; Dana M Brantley; Jin Chen
Journal:  Cytokine Growth Factor Rev       Date:  2002-02       Impact factor: 7.638

Review 2.  Pancreatic cancer: pathogenesis, prevention and treatment.

Authors:  Fazlul H Sarkar; Sanjeev Banerjee; Yiwei Li
Journal:  Toxicol Appl Pharmacol       Date:  2006-11-11       Impact factor: 4.219

3.  EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth.

Authors:  Megumi Iiizumi; Masayo Hosokawa; Akio Takehara; Suyoun Chung; Toru Nakamura; Toyomasa Katagiri; Hidetoshi Eguchi; Hiroaki Ohigashi; Osamu Ishikawa; Yusuke Nakamura; Hidewaki Nakagawa
Journal:  Cancer Sci       Date:  2006-09-05       Impact factor: 6.716

4.  Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.

Authors:  Shaji Abraham; Deborah W Knapp; Liang Cheng; Paul W Snyder; Suresh K Mittal; Dinesh S Bangari; Michael Kinch; Lan Wu; Jay Dhariwal; Sulma I Mohammed
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma.

Authors:  Christopher J Herrem; Tomohide Tatsumi; Kathleen S Olson; Keisuke Shirai; James H Finke; Ronald M Bukowski; Ming Zhou; Amy L Richmond; Ithaar Derweesh; Michael S Kinch; Walter J Storkus
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

Review 6.  EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics.

Authors:  Reneé C Ireton; Jin Chen
Journal:  Curr Cancer Drug Targets       Date:  2005-05       Impact factor: 3.428

7.  Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis.

Authors:  Weijie Yuan; Zhikang Chen; Shaobin Wu; Jie Ge; Shi Chang; Xianwei Wang; Jingxiang Chen; Zihua Chen
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

8.  EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.

Authors:  Aparna A Kamat; Donna Coffey; William M Merritt; Elizabeth Nugent; Diana Urbauer; Yvonne G Lin; Creighton Edwards; Russell Broaddus; Robert L Coleman; Anil K Sood
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

9.  Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.

Authors:  Lin-Fang Wang; Emmanouil Fokas; Michael Bieker; Frank Rose; Peter Rexin; Yuan Zhu; Axel Pagenstecher; Rita Engenhart-Cabillic; Han-Xiang An
Journal:  Oncol Rep       Date:  2008-01       Impact factor: 3.906

10.  Expression of EphA2 in human astrocytic tumors: correlation with pathologic grade, proliferation and apoptosis.

Authors:  Xia Li; Yingmei Wang; Yazhou Wang; Haining Zhen; Hao Yang; Zhou Fei; Jianning Zhang; Weiping Liu; Yangang Wang; Xiang Zhang
Journal:  Tumour Biol       Date:  2007-05-21
View more
  25 in total

1.  Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  Pathol Oncol Res       Date:  2013-09-11       Impact factor: 3.201

2.  Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice.

Authors:  Jessica L Dries; Susan D Kent; Jitka A I Virag
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

3.  EphB1 Suppression in Acute Myelogenous Leukemia: Regulating the DNA Damage Control System.

Authors:  K R Kampen; F J G Scherpen; G Garcia-Manero; H Yang; G J L Kaspers; J Cloos; C M Zwaan; M M van den Heuvel-Eibrink; S M Kornblau; E S J M De Bont
Journal:  Mol Cancer Res       Date:  2015-05-05       Impact factor: 5.852

Review 4.  Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Authors:  Dana M Brantley-Sieders
Journal:  Semin Cell Dev Biol       Date:  2011-10-21       Impact factor: 7.727

5.  A comprehensive map of the human urinary proteome.

Authors:  Arivusudar Marimuthu; Robert N O'Meally; Raghothama Chaerkady; Yashwanth Subbannayya; Vishalakshi Nanjappa; Praveen Kumar; Dhanashree S Kelkar; Sneha M Pinto; Rakesh Sharma; Santosh Renuse; Renu Goel; Rita Christopher; Bernard Delanghe; Robert N Cole; H C Harsha; Akhilesh Pandey
Journal:  J Proteome Res       Date:  2011-05-09       Impact factor: 4.466

6.  MicroRNA-335 suppresses the proliferation, migration, and invasion of breast cancer cells by targeting EphA4.

Authors:  Yilong Dong; Yang Liu; Aimei Jiang; Ruiqian Li; Min Yin; Yanmei Wang
Journal:  Mol Cell Biochem       Date:  2017-08-09       Impact factor: 3.396

7.  Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.

Authors:  Xifeng Wu; Liang Wang; Yuanqing Ye; Jeremiah A Aakre; Xia Pu; Gee-Chen Chang; Pan-Chyr Yang; Jack A Roth; Randolph S Marks; Scott M Lippman; Joe Y Chang; Charles Lu; Claude Deschamps; Wu-Chou Su; Wen-Chang Wang; Ming-Shyan Huang; David W Chang; Yan Li; V Shane Pankratz; John D Minna; Waun Ki Hong; Michelle A T Hildebrandt; Chao Agnes Hsiung; Ping Yang
Journal:  Cancer Res       Date:  2013-05-23       Impact factor: 12.701

8.  Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.

Authors:  Constantinos Giaginis; Paraskevi Alexandrou; Elpida Poulaki; Ioanna Delladetsima; Constantinos Troungos; Efstratios Patsouris; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2015-07-30       Impact factor: 3.201

9.  Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.

Authors:  Emily S Humphrey; Shih-Ping Su; Adnan M Nagrial; Falko Hochgräfe; Marina Pajic; Gillian M Lehrbach; Robert G Parton; Alpha S Yap; Lisa G Horvath; David K Chang; Andrew V Biankin; Jianmin Wu; Roger J Daly
Journal:  Mol Cell Proteomics       Date:  2016-06-03       Impact factor: 5.911

Review 10.  The role of EphA7 in different tumors.

Authors:  Xiangyi Chen; Dechen Yu; Haiyu Zhou; Xiaobo Zhang; Yicun Hu; Ruihao Zhang; Xidan Gao; Maoqiang Lin; Taowen Guo; Kun Zhang
Journal:  Clin Transl Oncol       Date:  2022-02-02       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.